India Gabapentin Market to be grow by CAGR of 6.31% during the forecast period
Growing epilepsy and
restless legs syndrome is expected to drive the India Gabapentin Market in the forecast period 2027-2031
According to TechSci Research report, “India Gabapentin
Market - By Region, Competition, Forecast &
Opportunities, 2031F”, The India Gabapentin Market was valued at
USD 74.52 Million in 2025 and is expected to reach USD 108.57 Million by 2031,
growing with a CAGR of 6.31% in the forecast period.
The
India gabapentin market is undergoing robust expansion, fueled by a convergence
of demographic, clinical, and infrastructural factors. Gabapentin, an
anticonvulsant and nerve pain medication, has become a mainstay in the
treatment of conditions such as epilepsy, diabetic neuropathy, post-herpetic
neuralgia, and fibromyalgia. With the sharp rise in non-communicable diseases
across the country, particularly diabetes, the incidence of neuropathic pain is
increasing rapidly, creating sustained demand for gabapentin-based therapies.
India’s diabetic population currently exceeds 77 million, with a significant
percentage experiencing peripheral neuropathic symptoms. This clinical need is
compounded by the country's aging population, as over 120 million people are
aged 60 and above—an age group particularly vulnerable to nerve-related
disorders and chronic pain. Gabapentin’s favorable safety profile and
versatility have also led to its increased off-label use in treating anxiety
disorders, bipolar disorder, insomnia, and chronic back pain, further
broadening its clinical application and market potential.
The Indian pharmaceutical industry, known globally for its strength in generics, has capitalized on gabapentin’s off-patent status. In-house manufacturing dominates the market, with major Indian pharma players investing heavily in domestic production to ensure cost-effectiveness, quality control, and brand reliability. This is particularly advantageous in a regulatory environment that emphasizes affordability and essential drug access. Many companies also export gabapentin to regulated markets, leveraging India’s WHO-GMP and USFDA-compliant facilities. Contract manufacturing also contributes significantly, supporting smaller brands and ensuring market supply flexibility. Regional demand is led by the southern states, where better healthcare infrastructure, specialist availability, and chronic disease awareness have driven higher diagnosis and prescription rates.
Key market trends include the growing adoption of extended-release (ER) formulations, which offer improved patient adherence and therapeutic outcomes by reducing dosing frequency and minimizing side effects. Fixed-dose combinations of gabapentin with agents like methylcobalamin or nortriptyline are gaining traction, particularly in pain management regimens. Digital health platforms, teleconsultations, and the rise of e-pharmacies have expanded access to gabapentin in semi-urban and rural areas, albeit awareness and diagnosis in these regions remain limited. About 65% of India’s population resides in rural areas, yet a large portion remains underserved due to lack of neurologists, diagnostic tools, and health literacy. This gap presents both a challenge and an opportunity for market players seeking to expand their reach.
Despite strong demand drivers, the market faces several hurdles. Misuse and over-prescription—especially in off-label scenarios—have raised concerns among clinicians and regulators. Reports of co-abuse with opioids or sedatives have triggered discussions on tighter prescription monitoring. Price control policies imposed by the National Pharmaceutical Pricing Authority (NPPA) can restrict profit margins, impacting innovation and formulation upgrades. Another critical concern is the dependency on imported active pharmaceutical ingredients (APIs), particularly from China. Disruptions in the supply of these raw materials can lead to product shortages and cost volatility.
In the coming years, the India gabapentin market is expected to maintain its upward trajectory, supported by chronic disease trends, evolving treatment protocols, and increasing healthcare penetration. Strategic investment in rural awareness programs, physician training, and domestic API manufacturing will be key to unlocking the market's full potential. As public and private healthcare sectors continue to collaborate and digital infrastructure deepens, gabapentin is well-positioned to remain a cornerstone of neurological and pain management therapies across India.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "India Gabapentin Market ”
India Gabapentin Market is segmented into source, form,
strength, distribution channel, application, end user, regional distribution,
and company.
Based on distribution channel, in the India gabapentin
market, offline channels remain dominant over online platforms. Traditional
retail pharmacies, hospital dispensaries, and doctor-linked chemist outlets
account for the majority of gabapentin sales. This dominance is primarily due
to patient behavior, prescription requirements, and the strong presence of
physical pharmacies across both urban and semi-urban areas. Many patients,
especially in tier 2 and tier 3 cities, prefer face-to-face consultations with
physicians and tend to purchase medicines immediately from nearby pharmacies.
Gabapentin is a prescription-based drug, and its sale
is regulated. While online pharmacies have grown rapidly in urban areas,
especially post-COVID-19, their share in the gabapentin segment is still
limited due to restrictions on prescription verification and delivery timelines
in remote areas. Offline pharmacies benefit from strong physician-pharmacist
networks, ensuring faster access and better trust among patients. Although
online platforms are gaining traction—supported by discounts, convenience, and
teleconsultations—the lack of digital literacy and regulatory barriers limit
their penetration. For now, offline channels lead the market due to
accessibility, immediacy, and established patient habits.
Based on application, neuropathic pain was the dominant
segment in the India gabapentin market, surpassing indications like epilepsy,
restless legs syndrome (RLS), seizures, and others. This dominance is primarily
driven by the increasing prevalence of diabetes and other chronic conditions that
lead to nerve damage and long-term pain. Diabetic neuropathy, post-herpetic
neuralgia, and fibromyalgia are among the most common forms of neuropathic pain
treated with gabapentin. India has over 77 million people living with diabetes,
and approximately 20–25% of them experience peripheral neuropathy. This creates
a large patient base requiring continuous treatment, making neuropathic pain
the most significant driver of gabapentin prescriptions. Gabapentin’s ability
to provide effective relief with a relatively low risk of dependency makes it a
preferred first-line treatment in both public and private healthcare settings.
While gabapentin is also used for epilepsy and
seizures, those conditions are less prevalent compared to chronic pain
syndromes. RLS and other off-label uses contribute smaller market shares. The
long-term nature of neuropathic pain and its growing diagnosis, particularly in
urban areas, further solidify this segment’s lead in the Indian gabapentin
market.
Based on region, the eastern region of India is
currently the fastest-growing in the gabapentin market, driven by improving
healthcare infrastructure, rising awareness of chronic neurological conditions,
and expanding access to diagnosis and treatment. States like West Bengal,
Odisha, Bihar, and Jharkhand are witnessing increased healthcare investments
and the establishment of more diagnostic centers and specialty clinics, which
is enhancing the identification of conditions like diabetic neuropathy,
epilepsy, and chronic nerve pain.
This region has historically been underserved in terms
of specialized care, but recent government and private sector efforts are
bridging the gap. With a large diabetic population and a growing elderly
demographic, demand for gabapentin is increasing rapidly. In addition,
awareness campaigns and mobile healthcare initiatives are making inroads into
semi-urban and rural areas, where previously, such conditions were often
overlooked or misdiagnosed. As healthcare access and affordability improve
across the eastern states, this region is expected to continue its strong
growth trajectory in the gabapentin market.
Major companies operating in India Gabapentin
Market are:
·
Aurobindo Pharma
Ltd.
·
Glenmark
Pharmaceuticals Ltd.
·
Sun Pharmaceuticals
Industries Ltd.
·
Alkem Laboratories
Ltd.
·
Intas
Pharmaceuticals Ltd.
·
Hetero Drugs Ltd.
·
Silverline Chemicals
Ltd.
·
Taj Pharmaceuticals
Ltd.
·
Divis Laboratories
Ltd.
·
Unnati
Pharmaceuticals Pvt. Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The India gabapentin market is expanding steadily due to
the growing burden of neurological and chronic pain disorders. Gabapentin,
primarily used for neuropathic pain and epilepsy, is increasingly prescribed
for off-label conditions like anxiety and insomnia. The rise in diabetes and an
aging population has significantly increased the need for long-term pain
management solutions. While urban centers drive most of the demand, emerging
markets in rural and tier 2 cities are contributing to growth through improved
healthcare access. Generic dominance, cost-effective production, and a strong
domestic pharmaceutical base continue to support market expansion across public
and private healthcare segments”, said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“India Gabapentin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule, Others), By Strength (100 mg, 200 mg, 300 mg, 400 mg, Others), By Distribution Channel (Online v/s Offline), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome (RLS), Seizures, Others), By End User (Adult v/s Paediatric), By Company, By Region, Competition, Forecast & Opportunities, 2021-2031F”, has evaluated the future growth potential of India Gabapentin
Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in India Gabapentin
Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com